185 related articles for article (PubMed ID: 23783833)
1. Access to subsidized ACT and malaria treatment--evidence from the first year of the AMFm program in six districts in Uganda.
Fink G; Dickens WT; Jordan M; Cohen JL
Health Policy Plan; 2014 Jul; 29(4):517-27. PubMed ID: 23783833
[TBL] [Abstract][Full Text] [Related]
2. Subsidising artemisinin-based combination therapy in the private retail sector.
Opiyo N; Yamey G; Garner P
Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009926. PubMed ID: 26954551
[TBL] [Abstract][Full Text] [Related]
3. Trends in availability and prices of subsidized ACT over the first year of the AMFm: evidence from remote regions of Tanzania.
Yadav P; Cohen JL; Alphs S; Arkedis J; Larson PS; Massaga J; Sabot O
Malar J; 2012 Aug; 11():299. PubMed ID: 22929587
[TBL] [Abstract][Full Text] [Related]
4. Closing the access barrier for effective anti-malarials in the private sector in rural Uganda: consortium for ACT private sector subsidy (CAPSS) pilot study.
Talisuna AO; Daumerie PG; Balyeku A; Egan T; Piot B; Coghlan R; Lugand M; Bwire G; Rwakimari JB; Ndyomugyenyi R; Kato F; Byangire M; Kagwa P; Sebisubi F; Nahamya D; Bonabana A; Mpanga-Mukasa S; Buyungo P; Lukwago J; Batte A; Nakanwagi G; Tibenderana J; Nayer K; Reddy K; Dokwal N; Rugumambaju S; Kidde S; Banerji J; Jagoe G
Malar J; 2012 Oct; 11():356. PubMed ID: 23107021
[TBL] [Abstract][Full Text] [Related]
5. Do price subsidies on artemisinin combination therapy for malaria increase household use? Evidence from a repeated cross-sectional study in remote regions of Tanzania.
Cohen JL; Yadav P; Moucheraud C; Alphs S; Larson PS; Arkedis J; Massaga J; Sabot O
PLoS One; 2013; 8(7):e70713. PubMed ID: 23923018
[TBL] [Abstract][Full Text] [Related]
6. Effect of the Affordable Medicines Facility--malaria (AMFm) on the availability, price, and market share of quality-assured artemisinin-based combination therapies in seven countries: a before-and-after analysis of outlet survey data.
Tougher S; ; Ye Y; Amuasi JH; Kourgueni IA; Thomson R; Goodman C; Mann AG; Ren R; Willey BA; Adegoke CA; Amin A; Ansong D; Bruxvoort K; Diallo DA; Diap G; Festo C; Johanes B; Juma E; Kalolella A; Malam O; Mberu B; Ndiaye S; Nguah SB; Seydou M; Taylor M; Rueda ST; Wamukoya M; Arnold F; Hanson K
Lancet; 2012 Dec; 380(9857):1916-26. PubMed ID: 23122217
[TBL] [Abstract][Full Text] [Related]
7. Experience of healthcare personnel on Co-payment mechanism and the implications on its use in private drug outlets in Uganda.
Ocan M; Bakubi R; Nakalembe L; Ekusai-Sebatta D; Sam N
PLoS One; 2024; 19(5):e0297416. PubMed ID: 38758832
[TBL] [Abstract][Full Text] [Related]
8. Changes in the availability and affordability of subsidised artemisinin combination therapy in the private drug retail sector in rural Ghana: before and after the introduction of the AMFm subsidy.
Ansah EK; Whitty CJ; Bart-Plange C; Gyapong M
Int Health; 2016 Nov; 8(6):427-432. PubMed ID: 27744327
[TBL] [Abstract][Full Text] [Related]
9. What happened to anti-malarial markets after the Affordable Medicines Facility-malaria pilot? Trends in ACT availability, price and market share from five African countries under continuation of the private sector co-payment mechanism.
; Tougher S; Hanson K; Goodman C
Malar J; 2017 Apr; 16(1):173. PubMed ID: 28441956
[TBL] [Abstract][Full Text] [Related]
10. Has Tanzania embraced the green leaf? Results from outlet and household surveys before and after implementation of the Affordable Medicines Facility-malaria.
Thomson R; Festo C; Johanes B; Kalolella A; Bruxvoort K; Nchimbi H; Tougher S; Cairns M; Taylor M; Kleinschmidt I; Ye Y; Mann A; Ren R; Willey B; Arnold F; Hanson K; Kachur SP; Goodman C
PLoS One; 2014; 9(5):e95607. PubMed ID: 24816649
[TBL] [Abstract][Full Text] [Related]
11. Insights into the Affordable Medicines Facility-malaria in Ghana: the role of caregivers and licensed chemical sellers in four regions.
Adjei AA; Winch P; Laar A; Sullivan DJ; Sakyi KS; Stephens JK; Adjei GO; Boateng IA; Aubyn VN; Kubio C; Tuakli J; Vanotoo L; Bortei BB; Amo-Addae M; Sorvor F; Coleman N; Dalglish S; Owusu R; Gebreyesus T; Essuman E; Greene R; Ankomah E; Houston K; Bart-Plange C; Salamat S; Addison EA; Quakyi IA
Malar J; 2016 May; 15(1):263. PubMed ID: 27160685
[TBL] [Abstract][Full Text] [Related]
12. A pharmacy too far? Equity and spatial distribution of outcomes in the delivery of subsidized artemisinin-based combination therapies through private drug shops.
Cohen JM; Sabot O; Sabot K; Gordon M; Gross I; Bishop D; Odhiambo M; Ipuge Y; Ward L; Mwita A; Goodman C
BMC Health Serv Res; 2010 Jul; 10 Suppl 1(Suppl 1):S6. PubMed ID: 20594372
[TBL] [Abstract][Full Text] [Related]
13. Improving rational use of ACTs through diagnosis-dependent subsidies: Evidence from a cluster-randomized controlled trial in western Kenya.
Prudhomme O'Meara W; Menya D; Laktabai J; Platt A; Saran I; Maffioli E; Kipkoech J; Mohanan M; Turner EL
PLoS Med; 2018 Jul; 15(7):e1002607. PubMed ID: 30016316
[TBL] [Abstract][Full Text] [Related]
14. Accessibility, availability and affordability of anti-malarials in a rural district in Kenya after implementation of a national subsidy scheme.
Smith N; Obala A; Simiyu C; Menya D; Khwa-Otsyula B; O'Meara WP
Malar J; 2011 Oct; 10():316. PubMed ID: 22029829
[TBL] [Abstract][Full Text] [Related]
15. Does subsidizing the private for-profit sector benefit the poor? Evidence from national antimalarial subsidies in Nigeria and Uganda.
Tougher S; Hanson K; Goodman CA
Health Econ; 2021 Sep; 30(10):2510-2530. PubMed ID: 34291524
[TBL] [Abstract][Full Text] [Related]
16. The Affordable Medicines Facility-malaria--a success in peril.
Talisuna AO; Adibaku S; Amojah CN; Amofah GK; Aubyn V; Dodoo A; Juma E; Jackou DH; Mkude S; Okui AP; Ramarosandratana B; Shija SJ
Malar J; 2012 Nov; 11():370. PubMed ID: 23137141
[TBL] [Abstract][Full Text] [Related]
17. Artemisinin-based combination therapy availability and use in the private sector of five AMFm phase 1 countries.
Davis B; Ladner J; Sams K; Tekinturhan E; de Korte D; Saba J
Malar J; 2013 Apr; 12():135. PubMed ID: 23607504
[TBL] [Abstract][Full Text] [Related]
18. Copayment mechanism in selected districts of Uganda: Availability, market share and price of quality assured artemisinin-based combination therapies in private drug outlets.
Ocan M; Nambatya W; Otike C; Nakalembe L; Nsobya S
PLoS One; 2024; 19(3):e0295198. PubMed ID: 38536824
[TBL] [Abstract][Full Text] [Related]
19. Impact of introducing subsidized combination treatment with artemether-lumefantrine on sales of anti-malarial monotherapies: a survey of private sector pharmacies in Huambo, Angola.
Lussiana C; Floridia M; Martinho do Rosário J; Fortes F; Allan R
Trans R Soc Trop Med Hyg; 2016 Dec; 110(10):588-596. PubMed ID: 27856948
[TBL] [Abstract][Full Text] [Related]
20. The association between price, competition, and demand factors on private sector anti-malarial stocking and sales in western Kenya: considerations for the AMFm subsidy.
O'Meara WP; Obala A; Thirumurthy H; Khwa-Otsyula B
Malar J; 2013 Jun; 12():186. PubMed ID: 23738604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
